Skyrizi and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease. Skyrizi gained Crohn's approval in June 2022 based on the ADVANCE, MOTIVATE, and FORTIFY trials. Omvoh gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these two within-class options often weigh maintenance dosing, trial design, and GI familiarity with each drug. This guide walks through the skyrizi vs omvoh crohn's comparison.
Same Class, Two Molecules
Skyrizi (risankizumab) and Omvoh (mirikizumab) both bind the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 drives Th17 inflammation central to Crohn's disease pathology. The risankizumab vs mirikizumab comparison is a within-class decision, so the structural mechanism is shared, but the molecules differ in affinity, half-life, and the clinical programs that support each.
Trial Evidence: ADVANCE, MOTIVATE, FORTIFY vs VIVID-1
Skyrizi's Crohn's approval rests on ADVANCE and MOTIVATE (induction) and FORTIFY (maintenance). ADVANCE enrolled biologic-naive and biologic-experienced Crohn's patients, while MOTIVATE focused on biologic-experienced patients. Both showed significantly higher clinical remission and endoscopic response on Skyrizi vs placebo at week 12, with FORTIFY confirming durability through week 52. Omvoh's Crohn's approval rests on VIVID-1, a three-arm trial comparing mirikizumab with placebo and with ustekinumab (Stelara). VIVID-1 showed mirikizumab superior to placebo on co-primary endpoints of clinical remission and endoscopic response, with a key secondary endpoint establishing non-inferiority to Stelara. The VIVID-1 vs ADVANCE design difference matters because VIVID-1 provides direct comparator data against an established biologic, while ADVANCE/MOTIVATE used placebo controls.
Efficacy Comparison
No head-to-head trial has directly compared Skyrizi with Omvoh in Crohn's. Indirect comparisons from network meta-analyses suggest similar clinical remission rates between the two drugs, with potentially stronger endoscopic outcomes on Skyrizi based on FORTIFY week 52 data. For skyrizi vs omvoh effectiveness, current data does not establish a clear winner for clinical remission, and decision-making often defaults to dosing preference and insurance coverage.
Onset of Action
Both drugs produce clinically meaningful Crohn's response by week 12. Skyrizi's induction timing shows meaningful benefit by week 4 in some patients per ADVANCE, with clinical remission evaluated at week 12. Omvoh's VIVID-1 used a week 12 clinical remission endpoint. For patients in active flare who need rapid improvement, the two drugs are comparable in practice, and individual response variability often matters more than small differences in trial endpoints.
Safety Profiles
Both drugs have favorable safety profiles consistent with IL-23 p19 class effects. Long-term data from each drug's psoriasis program (for Skyrizi) and UC program (for Omvoh) supports low rates of serious infection and malignancy. For skyrizi vs omvoh side effects, common adverse events on both drugs include upper respiratory infections, injection site reactions, and headache. Neither drug has a black-box warning for lymphoma or other class-level serious adverse events seen with anti-TNFs. TB and hepatitis B screening is recommended before starting either drug.
Administration and Dosing
Skyrizi for Crohn's uses IV induction at weeks 0, 4, and 8 (600 mg per infusion), followed by subcutaneous maintenance of 360 mg every 8 weeks via a prefilled cartridge and on-body injector, per AbbVie's prescribing information. Omvoh for Crohn's uses IV induction at 900 mg every 4 weeks for three doses (weeks 0, 4, and 8), followed by subcutaneous maintenance at 300 mg every 4 weeks (administered as two 150 mg injections), per Lilly's prescribing information. For Crohn's patients comparing long-term dosing frequency, Skyrizi's every-8-week SC maintenance is less frequent than Omvoh's every-4-week SC maintenance. The maintenance cadence often matters to patients who travel frequently or prefer less frequent injections.
Injection Experience
Skyrizi's Crohn's maintenance (360 mg every 8 weeks) uses an on-body injector cartridge that delivers over several minutes. Omvoh's Crohn's maintenance (300 mg every 4 weeks, delivered as two 150 mg injections) requires two separate injections per dose. Some patients prefer the single-dose convenience of the Skyrizi device, while others find Omvoh's split injection manageable given the more frequent schedule. Device preference is worth discussing with your GI or infusion/pharmacy team.
Cost and Access
Both Skyrizi and Omvoh are branded biologics without biosimilar competition. Insurance coverage varies by plan, and prior authorization is typically required for both drugs in Crohn's. Manufacturer copay assistance programs exist for commercially insured patients on both drugs. Because Omvoh is newer to the Crohn's indication, some insurance plans may not yet cover it for Crohn's as readily as for UC, though this is evolving rapidly as formularies update.
Choosing With Your GI
For a Crohn's patient deciding between Skyrizi and Omvoh, Skyrizi tends to win on longer Crohn's track record, less frequent SC maintenance, and extensive real-world data. Omvoh tends to win on head-to-head comparator data against Stelara (VIVID-1) and the choice of clinicians who prefer molecules with directly compared active-drug benchmarks. Ask your GI which drug they have the most experience with, how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.